» Articles » PMID: 34991476

Distribution of Serotypes and Antibiotic Resistance of Invasive Pseudomonas Aeruginosa in a Multi-country Collection

Abstract

Background: Pseudomonas aeruginosa is an opportunistic pathogen that causes a wide range of acute and chronic infections and is frequently associated with healthcare-associated infections. Because of its ability to rapidly acquire resistance to antibiotics, P. aeruginosa infections are difficult to treat. Alternative strategies, such as a vaccine, are needed to prevent infections. We collected a total of 413 P. aeruginosa isolates from the blood and cerebrospinal fluid of patients from 10 countries located on 4 continents during 2005-2017 and characterized these isolates to inform vaccine development efforts. We determined the diversity and distribution of O antigen and flagellin types and antibiotic susceptibility of the invasive P. aeruginosa. We used an antibody-based agglutination assay and PCR for O antigen typing and PCR for flagellin typing. We determined antibiotic susceptibility using the Kirby-Bauer disk diffusion method.

Results: Of the 413 isolates, 314 (95%) were typed by an antibody-based agglutination assay or PCR (n = 99). Among the 20 serotypes of P. aeruginosa, the most common serotypes were O1, O2, O3, O4, O5, O6, O8, O9, O10 and O11; a vaccine that targets these 10 serotypes would confer protection against more than 80% of invasive P. aeruginosa infections. The most common flagellin type among 386 isolates was FlaB (41%). Resistance to aztreonam (56%) was most common, followed by levofloxacin (42%). We also found that 22% of strains were non-susceptible to meropenem and piperacillin-tazobactam. Ninety-nine (27%) of our collected isolates were resistant to multiple antibiotics. Isolates with FlaA2 flagellin were more commonly multidrug resistant (p = 0.04).

Conclusions: Vaccines targeting common O antigens and two flagellin antigens, FlaB and FlaA2, would offer an excellent strategy to prevent P. aeruginosa invasive infections.

Citing Articles

Novel broadly reactive monoclonal antibody protects against infection.

Mateu-Borras M, Dublin S, Kang J, Monroe H, Sen-Kilic E, Miller S Infect Immun. 2024; 93(1):e0033024.

PMID: 39670709 PMC: 11784295. DOI: 10.1128/iai.00330-24.


Role of R5 Pyocin in the Predominance of High-Risk Isolates.

Zhang L, Xu Q, Tan F, Deng Y, Hakki M, Shelburne S bioRxiv. 2024; .

PMID: 39416193 PMC: 11483031. DOI: 10.1101/2024.10.07.616987.


An unnatural amino acid dependent, conditional Pseudomonas vaccine prevents bacterial infection.

Pigula M, Lai Y, Koh M, Diercks C, Rogers T, Dik D Nat Commun. 2024; 15(1):6766.

PMID: 39117651 PMC: 11310302. DOI: 10.1038/s41467-024-50843-7.


Comparative genomics of Tn6411 transposons carrying the blaIMP-1 gene in Pseudomonas aeruginosa.

Zheng L, Wang Z, Guo J, Guan J, Lu G, Jing J PLoS One. 2024; 19(7):e0306442.

PMID: 38980842 PMC: 11232968. DOI: 10.1371/journal.pone.0306442.


Genomic Differences Associated with Resistance and Virulence in Isolates from Clinical and Environmental Sites.

Aroca Molina K, Gutierrez S, Benitez-Campo N, Correa A Microorganisms. 2024; 12(6).

PMID: 38930498 PMC: 11205572. DOI: 10.3390/microorganisms12061116.


References
1.
Vincent J . Vaccine development and passive immunization for Pseudomonas aeruginosa in critically ill patients: a clinical update. Future Microbiol. 2014; 9(4):457-63. DOI: 10.2217/fmb.14.10. View

2.
Walter J, Haller S, Quinten C, Karki T, Zacher B, Eckmanns T . Healthcare-associated pneumonia in acute care hospitals in European Union/European Economic Area countries: an analysis of data from a point prevalence survey, 2011 to 2012. Euro Surveill. 2018; 23(32). PMC: 6092912. DOI: 10.2807/1560-7917.ES.2018.23.32.1700843. View

3.
Pier G, Thomas D . Characterization of the human immune response to a polysaccharide vaccine from Pseudomonas aeruginosa. J Infect Dis. 1983; 148(2):206-13. DOI: 10.1093/infdis/148.2.206. View

4.
Sato H, Frank D . Multi-Functional Characteristics of the Pseudomonas aeruginosa Type III Needle-Tip Protein, PcrV; Comparison to Orthologs in other Gram-negative Bacteria. Front Microbiol. 2011; 2:142. PMC: 3131520. DOI: 10.3389/fmicb.2011.00142. View

5.
STANISLAVSKY E, Lam J . Pseudomonas aeruginosa antigens as potential vaccines. FEMS Microbiol Rev. 1998; 21(3):243-77. DOI: 10.1111/j.1574-6976.1997.tb00353.x. View